Avalyn Pharma Says Respiratory Research Publishes Detailed Results From Two Phase 1 Clinical Trials Of AP02 In Healthy Volunteers And Patients With IPF, Validating Inhaled Antifibrotic Approach

Results validate Avalyn’s approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability

Findings support continued advancement of AP02 for idiopathic pulmonary fibrosis (IPF); enrollment is on track in AURA Phase 2 trial with topline data expected late 2027

BOSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., ("Avalyn" or the "Company"), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02 (nebulized nintedanib) in healthy volunteers and patients with IPF. Topline data from the trials were previously presented at the American Thoracic Society (ATS) International Conference in May 2025.